triptolide + nab-paclitaxel

Triptolide + nab-paclitaxel is an experimental combination therapy being studied primarily for pancreatic ductal adenocarcinoma and other solid tumors. Triptolide is a diterpenoid triepoxide from the Chinese medicinal herb Tripterygium wilfordii, known for inhibiting cancer cell proliferation, inducing apoptosis, suppressing metastasis, and disrupting crucial cellular transcriptional machinery including RNA polymerase II and heat shock proteins such as HSP70. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a solvent-free, albumin-bound formulation of paclitaxel, a microtubule-stabilizing chemotherapeutic taxane that induces mitotic arrest and cell death. The combination shows a synergistic effect—preclinical and early clinical data indicate that co-administration results in greater inhibition of tumor growth, enhanced apoptosis, and increased survival in animal models as compared to each agent alone or standard-of-care therapies. Nab-paclitaxel offers improved tumor delivery via albumin-mediated transcytosis and reduces the need for premedication to prevent hypersensitivity compared to conventional paclitaxel. The rationale for the combination includes potential dose reduction and toxicity minimization while maintaining or improving anticancer efficacy. Triptolide is often delivered as the water-soluble prodrug Minnelide in preclinical and clinical studies[1][3][5][6][7][8][9].